Bayer emails/internal files point to misleading ads and refusal to disclose dangers of Yaz birth control

The Yaz, Yasmin and Ocella litigation takes another twist as internal Bayer emails obtained as part of the Multi-District Litigation (MDL) discovery process confirm that the mega-pharmaceutical company misled women about the health risks of the birth control pills.

As reported recently in numerous news reports, including one from Bloomberg News, emails and other internal company files obtained from Bayer confirm that the company sought to market Yaz and Yasmin birth-control pills for unapproved uses and misled women about the health risks the drug posed.

These documents were also used during depositions of key witnesses, many of which were taken by the attorneys at Zoll, Kranz & Borgess.

Click here to read more on the Bayer allegations of Yaz false advertising.

Apparently the ads worked, as Bayer’s contraceptives generated $1.58 billion last year alone.

Unfortunately, there are still thousands of women who remain unaware of the FDA’s recent finding that women taking Yaz, Yamin, Ocella and similar drospirenone-containing birth control pills are 74% more likely to suffer blood clots than women on other low-estrogen contraceptives!

The FDA set a hearing for December 8th to discuss these findings, and Zoll, Kranz & Borgess will continue to keep readers apprised of any new developments. Immediate questions and requests for additional information on injuries from Yaz birth control can be made by calling us toll-free at 888.841.9623 or by emailing us at anneke@toledolaw.com.